Stracquadanio Lab
AI and engineering biology for rare diseases
We are a multi-disciplinary research group based at the School of Biological Sciences at the University of Edinburgh interested in engineering and manufacturing highly effective therapies using two of the most disruptive technologies of the last 20 years: AI and engineering biology.
Our group is currently focusing on developing new therapies for the treatment of a class of rare diseases known as Lysosomal Storage Disease (LSDs). We are primarily focusing on Fabry disease, with the aim of bringing to the clinic a treatment that is both effective and sustainable to use.
Recent selected publications
- Construction and iterative redesign of synXVI a 903 kb synthetic Saccharomyces cerevisiae chromosome Nature Communications · 2025
- APEX: Automated Protein EXpression in Escherichia coli ACS Synthetic Biology · 2025
- Biofoundry-Scale DNA Assembly Validation Using Cost-Effective High-Throughput Long-Read Sequencing ACS Synthetic Biology · 2024
- Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors Leukemia · 2024
- Synthetic genome modules designed for programmable silencing of functions and chromosomes bioRxiv · 2024
Latest news
-
Matthias awarded the Young Investigator Award from the WORLD Symposium panel. Congratulations!
-
Alexandra Guckel joins the lab as PhD student of the Engineering Biology for Advanced Therapeutics Hub. Welcome!
-
Assunta Sansone joins the lab as a PhD student of the EastBIO CDT. Welcome!
-
Matthias awarded the School of Biological Sciences Postdoc Award for Research. Congratulations!
-
Martyna's work on automated protein expression in E. coli published in ACS synthetic biology.
-
Ginevra to present at the Gordon Conference on Synthetic Biology.